CHEK2 and breast carcinoma: FDA-approved therapies specific to breast cancer include Olaparib, which has demonstrated clinical efficacy for patients with ATM, BRCA1/2, and CHEK2 mutations, as well as alpelisib for patients with PIK3CA mutations [18].